系统性自身免疫性风湿病患者 COVID-19 后的免疫学和临床后遗症-猫眼课题宝

系统性自身免疫性风湿病患者 COVID-19 后的免疫学和临床后遗症

批准号：

10583192

负责人：

Jeffrey Andrew Sparks

金额：

$78.25万

依托单位：

BRIGHAM AND WOMEN'S HOSPITAL

依托单位国家：

美国

项目类别：

财政年份：

2023

资助国家：

美国

项目状态：

未结题

起止时间：

2023-02-01 至 2028-01-31

来源：

https://reporter.nih.gov/project-details/10583192

关键词：

2019-nCoV Acute Affect American Antibodies Antibody Response Autoantibodies Autoimmunity B-Lymphocytes Biophysics COVID-19 COVID-19 impact COVID-19 pandemic COVID-19 pathogenesis COVID-19 risk COVID-19 survivors Characteristics Chest Chest imaging Clinical Community Hospitals Complication Coronavirus Data Diagnostic Disease Disease Outbreaks Dose Effectiveness Etiology Evolution Fibrosis General Hospitals General Population High Resolution Computed Tomography Hospitals Humoral Immunities Image Immune Immune response Immunologics Immunomodulators Immunosuppressive Agents Infection Knowledge Lead Massachusetts Measures Medicine National Institute of Arthritis, and Musculoskeletal, and Skin Diseases Observational Study Outcome Patients Phenotype Post-Acute Sequelae of SARS-CoV-2 Infection Predisposition Principal Investigator Prospective cohort Pulmonary Fibrosis RNA vaccine Recommendation Research Respiratory Signs and Symptoms Retrospective cohort study Rheumatoid Arthritis Risk SARS-CoV-2 infection Sampling Source Symptoms System Systemic Lupus Erythematosus TNF gene Vaccinated Vaccination Vaccines Variant Viral Virus Diseases Virus Shedding Vulnerable Populations Woman Work autoimmune rheumatologic disease breakthrough infection cohort coronavirus disease fibrotic lung disease high risk inhibitor medical schools pandemic disease participant enrollment pathogen post-COVID-19 professor prospective prototype public health relevance respiratory response rheumatologist rituximab tertiary care therapy resistant vaccine immunogenicity virology

项目摘要

项目成果

Jeffrey Andrew Sparks的其他基金

相似基金

相关文献

中文摘要

翻译

项目摘要 500万美国人患有全身性自身免疫性风湿性疾病（SARD），如类风湿性关节炎（RA）和系统性红斑狼疮（SLE），患COVID-19的风险增加。用免疫调节剂进行SARO治疗可能导致对疫苗接种和感染的免疫应答减弱和失调。SARD的特征在于自身抗体形成和纤维化的倾向。这些因素可能使SARD面临短期结局不良的风险（例如，突破性感染，延长病毒脱落）和COVID-19急性后后遗症（PASC），其特征为延长COVID-19症状（>/=28天）。PASC临床应用价值高，

英文摘要

PROJECT SUMMARY The 5 million Americans living with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of poor COVID-19 outcomes. SARO treatment with immunomodulators may lead to blunted and dysregulated immune responses to vaccination and infection. SARDs are characterized by a predisposition to autoantibody formation and fibrosis. These factors may place SARDs at risk for poor short-term outcomes (e.g., breakthrough infection, prolonged viral shedding) and post-acute sequelae of COVID-19 (PASC), characterized by prolonged COVID-19 symptoms (>/=28 days). PASC is of high clinical and

期刊论文(0)

专著(0)

科研奖励(0)

会议论文